MARKET

AGRX

AGRX

Agile Therapeutics Inc
OTCPK
0.364
-0.036
-8.99%
Closed 15:40 04/12 EDT
OPEN
0.390
PREV CLOSE
0.400
HIGH
0.390
LOW
0.360
VOLUME
38.74K
TURNOVER
14.68K
52 WEEK HIGH
12.40
52 WEEK LOW
0.202
MARKET CAP
2.50M
P/E (TTM)
-0.0543
1D
5D
1M
3M
1Y
5Y
Agile Therapeutics Releases Updated Investor Presentation
TipRanks · 5d ago
Weekly Report: what happened at AGRX last week (0401-0405)?
Weekly Report · 6d ago
Weekly Report: what happened at AGRX last week (0325-0329)?
Weekly Report · 04/01 09:55
Agile Therapeutics’ Balancing Act: Funding Challenges Threaten R&D and Twirla Rollout
TipRanks · 03/30 06:01
AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023
Agile Therapeutics reported results for the fourth quarter of 2023. The company reported earnings per share of -$1.46 and revenue of $3.62 million. This was 11.18% below the analyst estimate for revenue of - $4.07 million.
Investorplace · 03/30 00:52
Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics reported quarterly losses of $1.46 per share. The company missed the analyst consensus estimate of $0.92 per share by 58.7%. The company also reported quarterly sales of $3.62 million which missed the estimate by 11.18 percent.
Benzinga · 03/28 12:17
Agile Therapeutics reports Q4 results
Seeking Alpha · 03/28 12:13
Agile Therapeutics: Q4 Earnings Snapshot
Agile Therapeutics Inc. Reports a loss of $4.5 million in its fourth quarter. The developer of prescription contraceptive products for women posted revenue of $3.6 million in the period. For the year, the company's loss narrowed to $6.71 per share.
Barchart · 03/28 07:22
More
About AGRX
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The Company commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

Webull offers Agile Therapeutics Inc stock information, including OTCPK: AGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGRX stock methods without spending real money on the virtual paper trading platform.